RAMPART Study Investigates Quality of Life Impact of Durvalumab and Tremelimumab in RCC - Sophie Merrick
Sophie Merrick
Sophie Merrick discusses patient-reported outcomes from RAMPART, evaluating adjuvant durvalumab plus tremelimumab versus observation in renal cell carcinoma.
Feasibility of Using an RNA-Seq Biomarker to Assign Therapy in the OPTIC RCC Trial - Pedro Barata
Pedro Barata
Pedro Barata discusses the OPTIC RCC trial, which uses RNA-sequencing biomarkers to guide treatment selection in metastatic clear cell renal cell carcinoma.
